4 Nov
2020

Life sciences IP dealmaking during the pandemic and beyond

Despite significant disruption to pharma and biotech M&A early this year, companies are continuing to pursue the IP-heavy deals that drive innovation in the industry. Far from a break with the past, in many respects there is strong continuity in the agreements being struck

Adam Houldsworth

Life sciences reporter

IAM

[email protected]